BioStock: Saniona strengthened its cash position and advanced through partnership
Saniona's key milestone in 2024 was securing an exclusive worldwide licensing agreement with Acadia Pharmaceuticals worth up to USD 610 million. This deal not only drives the continued development of SAN711 as a promising treatment for neurological disorders, but also accelerates the progression of multiple drug candidates in Saniona's pipeline.
- As we close 2024 and look ahead to 2025, I am pleased to share the significant progress Saniona has made in advancing our pipeline, strengthening our financial position, and setting the stage for multiple strategic opportunities, says Thomas Feldthus, CEO of Saniona.
Read the article at biostock.se:
This is a press release from BioStock - Connecting Innovation & Capital. https://www.biostock.se/